During Monday’s Morning trade, Shares of Gilead Sciences Inc. (NASDAQ:GILD), gained 1.57% to $121.68, hitting its highest level.
On May 31, Gilead Sciences, Inc. declared results from the Phase 3 clinical Study 119 of an investigational use of Zydelig® (idelalisib) in combination with ofatumumab in formerly-treated patients with chronic lymphocytic leukemia (CLL). In Study 119, there was a 73 percent reduction in the risk of disease progression or death in patients receiving Zydelig in combination with ofatumumab contrast to ofatumumab alone (hazard ratio (HR) = 0.27; 95 percent CI: 0.19, 0.39; p<0.0001). Detailed results will be presented recently during a poster session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #7023).
“The data stated recently reinforce preceding results showing that idelalisib, here in combination with the anti-CD20 monoclonal antibody ofatumumab, not only significantly improved overall and lymph node response rates, but more importantly progression-free survival in patients with formerly treated CLL,” said Jeffrey A. Jones, MD, MPH, Associate Professor of Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). “Importantly, these improvements were also observed in patients with genetic features typically associated with poor prognosis.”
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific.
Shares of Denbury Resources Inc. (NYSE:DNR), declined -1.89% to $6.24, during its current trading session, as oil prices fell below $63 a barrel on Monday, weighed down by concerns of a growing supply glut, paring earlier gains spurred by hopes that Greece might avert a default.
Oil prices retreated shortly after the opening of trading in New York, highlighting the pressure on the market from a crude oil supply overhang, particularly in the Atlantic basin.
Denbury Resources Inc. operates as an independent oil and natural gas company in the United States. The company primarily focuses on improved oil recovery utilizing carbon dioxide. It holds properties located in Mississippi, Texas, Louisiana, and Alabama in the Gulf Coast region; and in Montana, North Dakota, and Wyoming in the Rocky Mountain region.
Finally, Celgene Corporation (NASDAQ:CELG), gained 1.72%, and is now trading at $119.24.
Celgene International Sàrl, a wholly owned partner of Celgene Corporation, declared two analyses of MCL-002 (SPRINT), its multi-center, open-label, phase II randomized trial comparing Revlimid® (lenalidomide) with investigators’ choice (IC) in patients with relapsed/refractory mantle cell lymphoma (MCL), were presented at the European Hematology Association annual congress.
In the study, 254 patients were randomized 2:1 to receive either REVLIMID (n=170) or single agent cytarabine, rituximab, gemcitabine, fludarabine or chlorambucil (n=84). The primary efficacy endpoint was progression free survival, defined as the time from randomization to disease progression or death due to any cause. Secondary endpoints, counting health-related quality of life (QoL) were analyzed in an exploratory manner.
The primary endpoint, median PFS was significantly improved for lenalidomide vs IC (8.7 vs 5.2 months; HR=0.61, P=0.004). A pre-specified exploratory analysis was presented and examined progression-free survival (PFS) in sub-groups based on preceding therapies. Results examining the selected IC treatments in the study showed that REVLIMID offered a reduction in the risk of progression or death vs. each IC treatment. Contrast with lenalidomide, and taking into account the small number of patients per IC group, the risk reduction in PFS was 22% vs. rituximab (n=27), 56% vs. gemcitabine (n=20), 42% vs. fludarabine (n=18), 43% vs. chlorambucil (n=11), and 8% vs. cytarabine (n=8).
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
